Caplin Point Laboratories Ltd Share Price

Pharmaceuticals - Indian - Formulations

NSE: CAPLIPOINT Small Cap ISIN: INE475E01026

As on 22 January 2025 at 15:56 IST

₹2,177.35

-17.90

(-0.82%)

Sell Buy

About Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd. is a fast-growing pharmaceutical company with a significant presence in emerging markets. The company was founded in the year 1990. It operates in the pharmaceutical sector, specialising in developing, manufacturing, and marketing a wide range of pharmaceutical products. The company’s headquarters is situated in Chennai, Tamil Nadu, India. Caplin Point Laboratories offers a diverse range of products, including injectables, ophthalmic solutions, and various formulations under the WHO essential list. The company has over 4,000 product registrations globally and continues to expand its product pipeline with innovative therapies. Read More...

Over 1 Month

-9.20%

Over 6 Months

48.59%

Over 1 Year

45.95%

Over 3 Years

178.53%

Caplin Point Laboratories Ltd Summary

Close ₹ 2,177.35

Open ₹ 2,185

High ₹ 2,200

Low ₹ 2,116.85

Volume 91,673

Net Turnover (in ₹) ₹ 17,30,56,984.85

52Wk High ₹ 2,641

52Wk Low ₹ 1,225

52Wk High / Low

1,225

2,641

Caplin Point Laboratories Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 16,686.47

EPS (TTM) 39.94

Book Value (BV) 201.93

Div. Yield 0.23 %

P/E (TTM) 54.92

Price/Book Value 10.86

Delivery % 44.05 %

Face Value 2

Key Ratios

PE Ratio 35.27

PB Ratio 7.20

EV to Sales 15.66

PEG Ratio 1.68

ROA 20.36

ROE 22.43

Debt-Equity -

Net Profit Margin 45.39

Operating Profit Margin 62.86

Caplin Point Laboratories Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,761.04	1,522.71	1,308.16	1,084.83	904.54
Total Expenses	1,196.88	1,071.44	922.34	771.21	635.07
Profit Before Tax	564.43	451.35	385.82	313.62	269.46
Profit After Tax	461.42	376.99	308.45	251.43	215.08
Operating Profit after Depreciation	564.94	452.05	386.52	315.21	269.78

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	452.66	280.04	288.89	305.40	272.50
Total Non Current Assets	805.20	639.21	438.50	349.04	303.23
Total Current Assets	1,892.92	1,552.19	1,297.82	1,014.57	822.53
TOTAL ASSETS	2,698.12	2,191.40	1,736.32	1,363.61	1,125.76
Total Shareholder's Fund	2,315.71	1,880.48	1,483.93	1,185.83	947.91

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	318.39	271.37	336.73	268.61	44.68
Net Cash used in Investing Activities	-319.18	-216.40	-376.86	-29.68	-54.33
Net Cash used in Financing Activities	-38.07	-28.17	-40.68	-23.98	79.77

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	730.93	627.61	584.61	501.30	593.80
Total Expenses	365.19	334.46	334.30	291.36	340.67
Profit Before Tax	365.74	293.15	250.31	209.94	253.12
Profit After Tax	283.71	234.26	187.87	156.23	197.64
Operating Profit after Depreciation	365.84	293.27	250.40	210.11	253.31

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	165.79	156.85	163.33	182.68	166.93
Total Non Current Assets	819.21	641.48	448.49	348.35	310.59
Total Current Assets	703.10	661.70	605.67	512.64	380.74
TOTAL ASSETS	1,522.31	1,303.18	1,054.16	860.99	691.33
Total Shareholder's Fund	1,390.15	1,139.91	930.65	758.67	599.91

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	111.01	157.10	230.97	294.64	87.01
Net Cash used in Investing Activities	-118.13	-85.67	-276.02	-3.90	-41
Net Cash used in Financing Activities	-34.26	-30.42	-22.76	-3.47	-32.92

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	483.10	458.96	453.22	435.50	410.06
Total Expenses	318.44	307.15	307.99	293.22	272.66
Profit Before Tax	168.46	154.38	146.03	145.41	146
Profit After Tax	130.81	124.92	121.23	119.82	116.14
Operating Profit after Depreciation	185.43	170.39	162.58	159.48	157.94

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	207.93	185.64	139.38	132.83	179.22
Total Expenses	109.77	104.26	81.70	69.51	89.77
Profit Before Tax	134.66	96.68	86.91	74.43	107.20
Profit After Tax	105.74	72.54	69.88	55.45	82.10
Operating Profit after Depreciation	141.17	102.88	93.86	81.22	113.94

Caplin Point Laboratories Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 2,172.85

S2 2,150.45

S3 2,116.95

Pivot 2,206.35

R1 2,228.75

R2 2,262.25

R3 2,284.65

Moving Average

20 SMA 2,410.90

50 SMA 2,292.61

100 SMA 2,117.55

200 SMA 1,777.19

Caplin Point Laboratories Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Caplin Point Laboratories Ltd

₹2.5/Share

Announcement Date 23 Sep 2024

Record Date 23 Sep 2024

Div Yield 125%

Caplin Point Laboratories Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Caplin Point Laboratories Ltd	₹2,193.45	₹16,672.79
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Caplin Point Laboratories Ltd News

Caplin Point Laboratories receives USFDA approval for Levetiracetam in Sodium Chloride Injection

17 Jan 2025, 03:19 pm

Caplin Point Lab arm receives USFDA nod for seizures treatment injection

Caplin Point Laboratories has announced that its subsidiary, Caplin Steriles, has received final nod from United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Levetiracetam in sodium chloride injection.

17 Jan 2025, 12:57 pm

Caplin Point gains after receiving EIR report from USFDA for Tamil Nadu facility

Caplin Point Laboratories added 1.89% to Rs 2,557.50 after the company received the Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for its manufacturing facility located at Gummidipoondi, Tamil Nadu.

07 Jan 2025, 02:45 pm

Caplin Point arm gets USFDA nod for Difluprednate eye drops

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories has received final approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Difluprednate Ophthalmic Emulsion.

16 Dec 2024, 12:56 pm

Caplin Steriles receives USFDA approval for Difluprednate Ophthalmic Emulsion

16 Dec 2024, 12:42 pm

Caplin Point Laboratories Ltd Stock Analysis

Annual revenue for Caplin Point Laboratories Ltd increased by 16.46% to ₹730.93 crore in FY 2024 from ₹627.61 crore in FY 2023.
Annual Net Profit for Caplin Point Laboratories Ltd increased by 21.11% to ₹283.71 crore in FY 2024 from ₹234.26 crore in FY 2023.
Promoter Shareholding in Caplin Point Laboratories Ltd remains unchanged by 0.00% in the most recent quarter, from 70.56% in September 2024 to 70.56% in December 2024.
Caplin Point Laboratories Ltd delivered a 1-year return of 45.95% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Caplin Point Laboratories Ltd share price moved down by 0.82% from its previous close of INR ₹2,195.25. The latest Caplin Point Laboratories Ltd share price is INR ₹2,177.35.
Caplin Point Laboratories Ltd share price today has been at a low of 2,116.85 and a high of 2,200. Over the past 52 weeks, the Caplin Point Laboratories Ltd share price has seen a low of 1,225 and a high of 2,641.

About Caplin Point Laboratories Ltd

Caplin Point Laboratories Ltd. is a fast-growing pharmaceutical company with a significant presence in emerging markets. Established in 1990, the company initially focused on manufacturing ointments and creams. It specialises in producing other external applications as well. Over the years, it has expanded its product range and market reach, becoming a key player in the pharmaceutical industry.

Caplin Point Laboratories operates in the pharmaceutical sector, specialising in developing, manufacturing, and marketing a wide range of pharmaceutical products. These include finished formulations, active pharmaceutical ingredients (APIs), and injectables. The company has a strong presence in Latin America and Francophone Africa. It has recently entered regulated markets like the United States and the European Union.

With many years of experience, Caplin Point Laboratories has built a robust business model. This model caters predominantly to the bottom of the pyramid in the areas of its presence. The company’s headquarters is located in Chennai, Tamil Nadu, India. This strategic location supports its extensive operations and distribution networks across various regions.

The promoters of Caplin Point Laboratories include P Vijayalakshmi with a 24.71% stake in the company. C C Paarthipan serves as the Chairman of the company. A team of professional managerial promoters manages the operations of the company-

Sridhar Ganesan
R Nagendran
S Deenadayalan
D Sathyanarayanan

Caplin Point Laboratories offers diverse products, including injectables and ophthalmic solutions. It also provides various formulations under the WHO essential list. The company has over 4,000 product registrations globally. It continues to expand its product pipeline with innovative therapies. These products cater to various therapeutic areas, including psychiatric, neuropsychiatric, and oncology.

While Caplin Point Laboratories is a significant player in the pharmaceutical sector, it does not hold the number one position regarding market share or market capitalization. However, its unique business model and focus on emerging markets have positioned it as a key competitor in the industry. The registered office of Caplin Point Laboratories is in Perungudi, Chennai. The registrar's office is located on Ramakrishna Street, Chennai.

The vision of Caplin Point Laboratories Limited

Caplin Point Laboratories Ltd. envisions becoming a global leader in the pharmaceutical industry, focusing on innovation, quality, and accessibility. The company’s vision is rooted in its commitment to providing affordable healthcare solutions to underserved markets. This vision drives every aspect of its operations, from research and development to manufacturing. It also influences distribution strategies, ensuring accessibility to underserved markets.

The company aims to expand its presence in regulated markets like the United States and the European Union. This expansion is part of its strategy to diversify its market base and enhance its global footprint.

Innovation is at the heart of Caplin Point Laboratories’ vision. The company invests heavily in research and development to create new and effective pharmaceutical products. This focus on innovation helps the company stay ahead of industry trends and meet the evolving needs of patients. The company’s R&D efforts focus on developing complex generics and speciality products with high market potential.

Quality is another cornerstone of Caplin Point Laboratories’ vision. The company adheres to stringent quality control measures at every stage of production. This commitment to quality ensures that its products are safe, effective, and reliable.

Caplin Point Laboratories also envisions making healthcare accessible to all. The company focuses on emerging markets, where access to affordable healthcare is often limited. By providing cost-effective pharmaceutical solutions, the company aims to improve the quality of life for people in these regions. This focus on accessibility aligns with the company’s mission to serve the bottom of the pyramid.

Sustainability is a key aspect of Caplin Point Laboratories’ vision. The company is committed to conducting its operations in an environmentally responsible manner. This includes minimizing waste, reducing energy consumption, and implementing eco-friendly practices.

Caplin Point Laboratories’ vision also strongly emphasises corporate social responsibility (CSR). The company undertakes various CSR initiatives to improve healthcare, education, and community development.

A strong leadership team supports the company’s vision. The management is focused on driving growth and achieving the company’s strategic objectives. Their expertise and experience are crucial in steering the company towards its vision.

Caplin Point Laboratories’ vision is also reflected in its workforce. The company values its employees and invests in their development. This includes providing training and development opportunities to enhance their skills and knowledge.

The company’s vision extends to its stakeholders as well. Caplin Point Laboratories aims to create shareholder value by delivering consistent financial performance. The company’s growth strategy is focused on expanding its product portfolio, entering new markets, and enhancing operational efficiency. This approach ensures sustainable growth and long-term value creation for its stakeholders.

Caplin Point Laboratories’ vision is business growth and making a difference. The company is driven by a sense of purpose and a commitment to improving healthcare outcomes. This vision inspires the company to push boundaries, embrace challenges, and strive for excellence in everything it does.